Zhejiang Gongdong Medical Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Zhejiang Gongdong Medical Technology şirketinin toplam hissedar öz sermayesi CN¥1.7B ve toplam borcu CN¥60.0M olup, bu da borç-öz sermaye oranını 3.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.0B ve CN¥311.1M dir. Zhejiang Gongdong Medical Technology 'in FAVÖK'ü CN¥159.9M faiz karşılama oranı -6.5 dur. Şirketin CN¥514.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

3.6%

Borç/özkaynak oranı

CN¥60.00m

Borç

Faiz karşılama oranı	-6.5x
Nakit	CN¥513.97m
Eşitlik	CN¥1.68b
Toplam yükümlülükler	CN¥311.10m
Toplam varlıklar	CN¥1.99b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

There Are Reasons To Feel Uneasy About Zhejiang Gongdong Medical Technology's (SHSE:605369) Returns On Capital

Sep 23

Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) P/E Still Appears To Be Reasonable

Jun 07

Estimating The Intrinsic Value Of Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369)

Mar 28

Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Looks Just Right With A 27% Price Jump

Mar 06

Zhejiang Gongdong Medical Technology (SHSE:605369) Is Reinvesting At Lower Rates Of Return

Feb 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 605369 'nin kısa vadeli varlıkları ( CN¥925.8M ) kısa vadeli yükümlülüklerini ( CN¥272.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 605369 şirketinin kısa vadeli varlıkları ( CN¥925.8M ) uzun vadeli yükümlülüklerini ( CN¥38.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 605369 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 605369 şirketinin borç/öz sermaye oranı son 5 yılda 2.6% seviyesinden 3.6% seviyesine yükseldi.

Borç Kapsamı: 605369 'nin borcu işletme nakit akışı ( 361.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 605369 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Zhejiang Gongdong Medical Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Zhejiang Gongdong Medical Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 24%

There Are Reasons To Feel Uneasy About Zhejiang Gongdong Medical Technology's (SHSE:605369) Returns On Capital

Second quarter 2024 earnings released: EPS: CN¥0.76 (vs CN¥0.20 in 2Q 2023)

Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) announces an Equity Buyback for CNY 36 million worth of its shares.

Zhejiang Gongdong Medical Technology Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) P/E Still Appears To Be Reasonable

Zhejiang Gongdong Medical Technology Co., Ltd., Annual General Meeting, May 28, 2024

Zhejiang Gongdong Medical Technology Co., Ltd., Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 21% overvalued after recent price rise

Now 21% overvalued

Zhejiang Gongdong Medical Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Estimating The Intrinsic Value Of Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369)

Now 21% overvalued

Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Looks Just Right With A 27% Price Jump

Zhejiang Gongdong Medical Technology (SHSE:605369) Is Reinvesting At Lower Rates Of Return

Investor sentiment deteriorates as stock falls 21%

Now 20% overvalued

Zhejiang Gongdong Medical Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.88 in 3Q 2022)

New minor risk - Profit margin trend

First quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.84 in 1Q 2022)

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 19%

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

No independent directors

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: CN¥0.88 (vs CN¥0.67 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥1.03 (vs CN¥0.87 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥1.07 (vs CN¥0.83 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.87 (vs CN¥0.78 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.99 (vs CN¥0.53 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥3.48 (vs CN¥1.89 in FY 2019)

Zhejiang Gongdong Medical Technology Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 08, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥59.19

Third quarter earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin